Identification of Chochukei (Zhang Zhongjing) as the revolutionist of decoctions

2020 ◽  
Vol 7 (1) ◽  
pp. 17-23
Author(s):  
Toshinori Kawamoto ◽  
Hiroaki Nishijima ◽  
Masako Ohishi ◽  
Kazuto Isuzugawa ◽  
Ryuji Furihata ◽  
...  
Keyword(s):  
Zhang Zhongjing

Sphygmologie dans l’œuvre de Zhang Zhongjing

2011 ◽  
pp. 123-142
Author(s):  
Éric Marié
Keyword(s):  
Zhang Zhongjing

Zhang Ji (Zhang Zhongjing)

2016 ◽  
pp. 4611-4612
Author(s):  
Fabrizio Pregadio
Keyword(s):  
Zhang Zhongjing

scholarly journals Zhang Zhongjing, Medical Sage

2015 ◽  
Vol 2 (1) ◽  
pp. 1-2
Author(s):  
Min Li ◽  
Yongxuan Liang
Keyword(s):  
Zhang Zhongjing

Zhang Ji (Zhang Zhongjing)

2008 ◽  
pp. 2352-2353
Author(s):  
Fabrizio Pregadio
Keyword(s):  
Zhang Zhongjing

scholarly journals Insights from the Perspective of Traditional Chinese Medicine to Elucidate Association of Lily Disease and Yin Deficiency and Internal Heat of Depression

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Bingxian Shang ◽  
Hongxiu Zhang ◽  
Yanting Lu ◽  
Xiaoyu Zhou ◽  
Yong Wang ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Clinical Symptoms ◽  
Clinical Manifestations ◽  
Internal Heat ◽  
Psychological Problems ◽  
Yin Deficiency ◽  
Zhang Zhongjing ◽  
New Ideas ◽  
The Relationship

Lily disease was first recorded in Synopsis of the Golden Chamber by Zhang Zhongjing. It is a disease of heart and lung internal heat by Yin deficiency, which belongs to the category of emotion disease in Chinese medicine. In recent years, researchers believe that lily disease and depression syndrome of Yin deficiency and internal heat have many similarities in etiology, pathogenesis, and clinical manifestations. This review summarizes the clinical symptoms, etiology, pathogenesis, and therapeutic medication of lily disease and modern Yin-deficient internal heat depression and discusses the relationship between them. Furthermore, the relationship between coronavirus disease 2019 (COVID-19) and lily disease was discussed from the etiology, pathogenesis, and treatment. It provides new ideas for the treatment of COVID-19 and the treatment of psychological problems after recovery.

scholarly journals Guizhi Fuling Capsule Exhibits Antidysmenorrhea Activity by Inhibition of Cyclooxygenase Activity

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Weiran Zheng ◽  
Meng Li ◽  
Yongxiang Wang ◽  
Baojie Lv ◽  
Xinzhuang Zhang ◽  
...  
Keyword(s):  
Uterine Fibroids ◽  
Inhibitory Effect ◽  
Drug Formulation ◽  
Primary Dysmenorrhea ◽  
Limited Information ◽  
Dysfunctional Uterine Bleeding ◽  
Cyclooxygenase Activity ◽  
Zhang Zhongjing ◽  
Direct Inhibitory Effect ◽  
Cox2 Expression

Guizhi Fuling capsule (GZFLc) is a modern preparation from traditional Chinese Medicine. Guizhi Fuling was first prescribed by Zhang Zhongjing almost two thousand years ago for the treatment of primary dysmenorrhea. It has also been used to treat uterine fibroids, dysfunctional uterine bleeding, and endometriosis. Although effective against dysmenorrhea clinically, there are limited information on the mechanism of its action. The major components responsible for the activity are not well defined. The aim of this study has been to elucidate a mechanism that may facilitate the development of a bioactivity-based assay for quality control during drug formulation and manufacturing. Using an oxytocin-induced mouse dysmenorrhea model, we showed that oral administration of GZFLc at 150 and 300 mg/kg, dosages relevant to clinic usages, significantly suppressed oxytocin-induced writhing response. The antidysmenorrhea effect was also demonstrated by a rotarod assay. We showed that GZFLc treatment significantly prolonged the hanging time of mice on the rotating rod. Histological studies showed that GZFLc treatment reduced lamina propria edema, while no effect on COX2 expression was detected. GZFLc instead exhibited direct inhibitory effect against COX2, a critical enzyme that catalyzes arachidonic acid conversion to prostaglandins. By HPLC profiling, we showed that paeoniflorin, paeonol, and cinnamaldehyde are the major components from the corresponding plants. At 5 and 10 mg/kg, both paeoniflorin and paeonol were active against induced dysmenorrhea. The study not only links GZFLc antidysmenorrhea activity to COX2 inhibition but also uncovers a mechanism of action by which an assay can be developed for bioefficacy evaluation of GZFLc.

scholarly journals Gualou Xiebai Banxia decoction ameliorates Poloxamer 407-induced hyperlipidemia

2021 ◽  
Author(s):  
Mingzhu Luo ◽  
Rong Fan ◽  
Xiaoming Wang ◽  
Junyu Lu ◽  
Ping Li ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Pure Water ◽  
Abdominal Cavity ◽  
Plasma Lipid ◽  
Test Group ◽  
Poloxamer 407 ◽  
Zhang Zhongjing ◽  
Biochemical Analyzer ◽  
Automatic Biochemical Analyzer ◽  
Eastern Han

Ethnopharmacological relevance: Gualou Xiebai Banxia decoction (GLXBBX) is a well-known traditional Chinese herbal formula that was first discussed in the Synopsis of the Golden Chamber by Zhang Zhongjing in the Eastern Han Dynasty. In traditional Chinese medicine, GLXBBX is commonly prescribed to treat cardiovascular diseases, such as coronary heart disease and atherosclerosis. Objective: The present study aimed to examine GLXBBX’s preventative capacity and elucidate the potential molecular mechanism of Poloxamer 407 (P407)-induced hyperlipidemia in rats. Materials and Methods: Both the control and model groups received pure water, and the test group also received a GLXBBX decoction. For each administration, 3 mL of the solution was administered orally. To establish hyperlipidemia, a solution mixed with 0.25 g/kg P407 dissolved in 0.9% normal saline was injected slowly into the abdominal cavity. At the end of the study, the rats’ plasma lipid levels were calculated using an automatic biochemical analyzer to evaluate the preventative capability of the GLXBBX decoction, and the serum and liver of the rats were collected. Results: The GLXBBX decoction significantly improved P407-induced hyperlipidemia, including increased plasma triglycerides, aspartate aminotransferase elevation, and lipid accumulation. Moreover, GLXBBX decoction treatment increased lipoprotein lipase (LPL) activity and mRNA expression of LPL. Furthermore, GLXBBX significantly suppressed the mRNA expression of stearoyl-CoA desaturase (SCD1). Conclusion: GLXBBX significantly improved P407-induced hyperlipidemia, which may have been related to enhanced LPL activity, increased LPL mRNA expression, and decreased mRNA expression of SCD1.

Sign in / Sign up

Export Citation Format

Share Document